Needham & Company Reiterates a 'Buy' on OncoGenex (OGXI); Stock is Undervalued
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on OncoGenex Pharmaceuticals (NASDAQ: OGXI) price target of $26.00.
Needham analyst says, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


